Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $41.00.

A number of research firms have issued reports on ELVN. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st.

Insider Buying and Selling

In related news, CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $21.82, for a total value of $272,750.00. Following the completion of the sale, the chief executive officer owned 890,392 shares in the company, valued at approximately $19,428,353.44. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard A. Heyman sold 9,635 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the completion of the transaction, the director directly owned 25,545 shares in the company, valued at $639,391.35. The trade was a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 259,280 shares of company stock worth $6,635,968. Company insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after acquiring an additional 1,693 shares during the period. Goldman Sachs Group Inc. increased its stake in Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new stake in Enliven Therapeutics in the first quarter worth $578,000. KLP Kapitalforvaltning AS raised its holdings in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares during the period. Finally, TD Asset Management Inc bought a new position in shares of Enliven Therapeutics during the second quarter worth $1,342,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $25.87 on Tuesday. The business’s fifty day moving average price is $20.52 and its two-hundred day moving average price is $20.38. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -14.06 and a beta of 0.41. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. As a group, research analysts forecast that Enliven Therapeutics will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.